Mutant Browser

Download
Protein name Generic number Position Segment Mutation FoldChange or Qual Exp Type Ligand Reference Review
ada2b_human 6.34x34 370 TM6 T => K N/A N/A Pauwels PJ et al (2000)
ada2b_human 6.34x34 370 TM6 T => K N/A N/A Pauwels PJ et al (2001)
ada2b_human 3.49x49 109 TM3 D => A 1.133↑ K(d) (Binding - Radioligand saturation) RX821002 Ge H et al (2003) Vass M et al (2019)
ada2b_human 3.49x49 109 TM3 D => A 2.679↑ K(i) (Binding - Radioligand competition/displacement) clonidine Ge H et al (2003) Vass M et al (2019)
ada2b_human 3.49x49 109 TM3 D => A 2.444↑ K(i) (Binding - Radioligand competition/displacement) (-)-noradrenaline Ge H et al (2003) Vass M et al (2019)
ada2b_human 3.49x49 109 TM3 D => A 2.479↑ K(i) (Binding - Radioligand competition/displacement) (-)-adrenaline Ge H et al (2003) Vass M et al (2019)
ada2b_human 3.49x49 109 TM3 D => A 1.288↑ K(i) (Binding - Radioligand competition/displacement) oxymetazoline Ge H et al (2003) Vass M et al (2019)
ada2b_human 3.49x49 109 TM3 D => A 3.857↑ K(i) (Binding - Radioligand competition/displacement) dexmedetomidine Ge H et al (2003) Vass M et al (2019)
ada2b_human 3.49x49 109 TM3 D => A 1.284↑ K(i) (Binding - Radioligand competition/displacement) brimonidine (UK14304) Ge H et al (2003) Vass M et al (2019)
ada2b_human 3.49x49 109 TM3 D => A 2.456↑ K(i) (Binding - Radioligand competition/displacement) Levomedetomidine Ge H et al (2003) Vass M et al (2019)
Protein name Generic number Segment Position Mutation FoldChange or Qual Exp Type Ligand Reference Review


Residue

Diagrams

ICL1 R S L R ICL1ECL1 Y W Y F ECL1ICL2 A L E Y N S K R ICL2ECL2 Y K G D Q G P Q P R G R P Q C K L N Q ECL2ICL3 K G G P G Q G E S K Q P R P D H G G A L A S A K L P A L A S V A S A R E V N G H S K S T G E K E E G E T P E D T G T R A L P P S W A A L P N S G Q G Q K E G V C G A S P E D E A E E E E E E E E E E E E C E P Q A V P V S P A S A C S P P L Q Q P Q G S R V L A T L R G Q V L L G R G V G A I G G Q W W R R ICL3ECL3 P K H C K V ECL3N-term M D H Q D P Y S V Q N-termC-term R P W T Q T A W C-term A T A A I A A A I T F L I L F T I F G N A L V I L A V L T S A P Q N L F L V S L A A A D I L V A T L I I P F S L A N E L L G R R T W C E V Y L A L D V L F C T S S I V H L C A I S L D R Y W A V S R T P R R I K C I I L T V W L I A A V I S L P P L I E A W Y I L A S S I G S F F A P C L I M I L V Y L R I Y L I A K R S N R R G P R A R A Q L T R E K R F T F V L A V V I G V F V L C W F P F F F S Y S L G A I C P H G L F Q F F F W I G Y C N S S L N P V I Y T I F N Q D F R R F R R A I L C
Download: PNG | SVG Increased binding/potency: >5-fold, >10-fold; Reduced binding/potency: >5-fold, >10-fold; No/low effect (<5-fold); and N/A
A N G F I T F L I L F T I A A A I A A T 1 V S L A A A D I L V A L T I I P F S L A N 2 A C L H V I S S T C F L V D L A L Y V E 3 I K C I I L T V W L I A A V I S L P P L 4 Y V L I M I L C P A F F S G I S S A L I Y 5 A V V I G V F V L C W F P F F F S Y S L 6 V P N L S S N C Y G I W F F F Q F L G 7
Download: PNG | SVG




Residue Table


GPCRdb(A)
GPCRdb(A)
α2B-adrenoceptor
TM3
3x49 3.49x49 D109
TM6
6x34 6.34x34 T370